BRCA1 and ovarian cancer: All 10 patients were treated with camonsertib at ≥120 mg QD (3/4 schedule); five achieved clinical benefit and one with ovarian cancer harboring a BRCA1 reversion had a RECIST 1.1 cPR (Extended Data Fig. 6a).